Background. Influenza-associated morbidity and mortality has not decreased in the last decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza vaccine, a high-dose (HD) trivalent, inactivated influenza vaccine was developed.
Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1] [2] [3] . The protective efficacy of in-munogenicity and protective efficacy of influenza vaccine in this population.
A major determinant of protection against influenza is serum antibody to hemagglutinin (HA), which can be measured by hemagglutination inhibition (HAI) testing [7] [8] [9] . Therefore, efforts to improve vaccine efficacy in the elderly have focused on increasing serum HAI titers. One strategy has been to increase the HA dose, and several studies have demonstrated a dose-dependent increase in HAI antibodies [10] [11] [12] [13] [14] . The standard-dose (SD) vaccine (Fluzone; sanofi pasteur), a licensed trivalent, split-virion, inactivated influenza vaccine, contains the standard amount of HA (15 mg) for each of 3 virus strains. The investigational high-dose vaccine used in this trial (Fluzone HD; sanofi pasteur) contains 4 times the dose (60 mg) of the same antigens in the SD vaccine. In prior phase 1 and 2 studies involving medically stable, ambulatory adults у65 years old, high-dose (HD) vaccine induced significantly higher HAI titers than did SD vaccine, with minimal increased reactogenicity [11, 14] .
The primary objectives of the current phase 3 study were to evaluate lot-to-lot consistency for HD vaccine and use HAI titers to confirm that HD vaccine was associated with higher levels of immunogenicity than standard trivalent influenza vaccine in a large cohort of ambulatory adults у65 years of age. The study's secondary objectives were to evaluate the rates of local and systemic adverse effects. The overall goal of this study was to confirm the improved immunogenicity and safety profile of this new HD vaccine, to validate it as a safe and potentially more efficacious alternative to the standard licensed influenza vaccine for use in elderly patients. Study design. The study was conducted as a multicenter, randomized, double-blind, controlled trial during the fall of 2006. Subjects were assigned by block randomization in a 2:1 ratio (block size, 18) to receive either HD vaccine or SD vaccine. Subjects in the HD vaccine group were further randomized to receive 1 of the 3 vaccine lots.
METHODS

Vaccines. The investigational HD vaccine assessed in this tri
Participants. Subjects who were у65 years of age, living in the community, and medically stable were recruited. Volunteers were excluded for the following reasons: allergy to eggs, history of Guillain-Barré syndrome, immunodeficiency or receipt of immunosuppressive therapy, and active neoplastic disease. Written, informed consent was obtained prior to enrollment, and all procedures were reviewed and approved by local and central institutional review boards. The study was conducted in the United States in accordance with the Investigational New Drug (IND) regulations.
Clinical procedures. After a baseline blood sample was collected, vaccine-identifiable only by code-was administered as a single intramuscular injection in the deltoid muscle by use of a 22-gauge, 2.54-cm needle, and subjects were observed for 30 min. Participants measured their oral temperature daily and recorded injection site and systemic symptoms in a diary for 7 days after vaccination. At day 28 after vaccination, participants' medical histories were reviewed and second blood samples were obtained.
Approximately 6 months after vaccination, subjects were contacted by phone to document all concurrent serious adverse events (SAEs) and use of health care. Injection site reactionspain, erythema, and swelling-were categorized as mild, moderate, and severe. Pain was categorized as none (0), mild (1, easily tolerated), moderate (2, discomfort interferes with daily activity), and severe (3, incapacitating pain). Erythema and swelling were assessed in terms of the diameter of the maximum reaction size, and classified as follows: mild (!2.5 cm), moderate (у2.5-!5 cm), and severe (у5 cm). Systemic symptoms were graded as follows. Fever (oral temperature) was categorized as mild (у37.5ЊC-р38ЊC), moderate (138ЊC-р39ЊC), and severe (139ЊC). The symptoms of headache, malaise, and myalgia were considered mild if they were noticeable but did not interfere with daily activities, moderate if they interfered with daily activity, and severe if they prevented daily activities.
Laboratory assays. Serum samples were assessed for antibody to each of the 3 components of the vaccine by hemagglutination inhibition (HAI) testing performed in accordance with standard methods [15] . In brief, serial 2-fold dilutions of neuraminidase-treated serum samples were incubated with 4 HA units of influenza antigen and a chicken red blood cell suspension. After incubation, assay plates were evaluated for the ability of the serum antibodies to inhibit hemagglutination. The serum HAI titer was defined as the dilution factor of the highest serum dilution that completely inhibited hemagglutination. This assay was validated and performed using Good Laboratory Practice standards [16] .
Definition of end points. The lot consistency of HD vaccine was assessed for each virus strain by use of the pairwise ratios of the HAI geometric mean titers (GMTs) for recipients of the 3 lots of vaccine. Acceptable lot consistency was defined as a ratio for which the limits of the 95% confidence interval (CI) fell between 0.67 and 1.5 for all pairwise ratios for each vaccine Figure 1 . Flowchart showing distribution of trial participants in analysis groups (A) (immunogenicity analysis assessed data for subjects as randomized, and safety analysis assessed data for subjects as vaccinated) and in progress through trial stages (B). *Some subjects switched groups because of misrandomization. HD, high-dose influenza vaccine; SAE, serious adverse event; SD, standard-dose influenza vaccine.
strain. Results from the 3 lots of HD vaccine were pooled for further analyses after lot consistency had been demonstrated.
The immunogenicity of HD vaccine was assessed in terms of rates of seroconversion and ratio of GMTs for each virus strain, relative to the values obtained for the SD vaccine. Seroconversion was defined as either an increase in HAI titer from !1:10 to у1:40 after vaccination or a у4-fold increase in HAI titer after vaccination from a prevaccination titerу1: 10. Superiority was demonstrated if the lower limit of the 95% confidence interval for the difference in seroconversion rates (i.e., HD vaccine minus SD vaccine) was 110%, and noninferiority was shown if the lower limit of the 95% confidence interval was 1Ϫ10%. The ratio of the HAI GMTs for HD vaccine recipients and SD vaccine recipients was assessed for all vaccine strains; superiority was demonstrated if the lower limit of the 95% confidence interval for the ratio was 11.5, and noninferiority was defined as an HAI GMT ratio value 10.67. For HD vaccine to be considered superior to SD vaccine overall, for each measure it was required to demonstrate superiority for at least 2 of the 3 vaccine strains without demonstrating inferiority for any strain.
As secondary objectives, we also assessed the rate of seroprotection, defined as an HAI titer у1:40, and the safety profile of HD vaccine compared to SD vaccine. The systemic safety of HD vaccine was considered noninferior to that of SD vaccine if the upper limit of the 2-sided 95% confidence interval for the relative risk was !3. Post hoc analyses were conducted to determine whether age, sex, or the presence of underlying car- figure 1A ). There were no statistically significant differences between the HD and SD vaccine groups with respect to age, race, sex, or the presence of underlying diseases. COPD, chronic obstructive pulmonary disease.
diopulmonary disease affected the antibody response to HD vaccine, compared with the response to SD vaccine. We also compared the proportions of vaccinees who had HAI titers of at least 1:80 and 1:160.
Statistical methods. The sample size for this study was selected to achieve the primary objectives of demonstrating lot consistency and superiority of HD vaccine. A total sample size of 3896 was planned (2598 HD vaccine and 1298 SD vaccine) to provide 180% overall power to detect the primary immunologic objectives and allow for a 5% drop-out rate. Although this study was not powered to make safety determinations, it had 199% power to detect a 3-fold increase in the number of subjects experiencing solicited systemic reactions.
The full analysis set (FAS) was defined as the set of subjects who received a study vaccine and provided data for at least 1 postvaccination assessment. The immunogenicity analysis was performed on the FAS according to the vaccine the subjects were randomized to receive, whereas the safety analysis was performed on the FAS according to the vaccine subjects actually received. For analysis of lot consistency, at 1 month after vaccination we analyzed HAI GMT ratios for the pairwise comparisons of the 3 HD vaccine lots and their associated 95% confidence intervals for each virus strain. To evaluate the superiority of the HD vaccine, 95% confidence intervals were calculated for the HAI GMT ratios and for the difference in seroconversion rates for the pooled HD vaccine lots and compared to the values for SD vaccine. All the 95% confidence intervals were calculated using normal approximation. Demographic characteristics, safety data, and other secondary endpoints for HAI titers were analyzed using descriptive statistics. The statistical analysis was performed using SAS (version 8.2; SAS Institute).
RESULTS
Between 9
October and 21 December 21, 2006, a total of 3876 subjects were randomized at 30 centers throughout the United States. Twenty-five subjects were excluded from the immunogenicity analysis, as shown in figure 1A ; this analysis was performed using data for the 2576 subjects randomized to receive 1 of 3 lots of HD vaccine and the 1275 participants randomized to receive SD vaccine. The safety analysis was performed using actual vaccination data, but 18 subjects were excluded from this analysis because researchers could not verify the vaccine formulation they received. Overall, 46 subjects who received HD vaccine and 32 subjects who received SD vaccine withdrew prior to the end of the study ( figure 1B ). There were 33 participants who withdrew because of SAEs, but none of their SAEs were considered to be related to vaccination. The mean ‫ע(‬ SD) age of study participants was 73 ‫ע‬ 6 years (range, 65-97 years), and there were no statistically significant differences between the groups that received different lots of HD vaccine or between the HD group and the SD group with respect to age, race, sex, or the presence of underlying diseases (table 1) .
Immunogenicity analysis. Baseline and postvaccination HAI GMTs for subjects who received 1 of the 3 HD vaccine lots were comparable (data not shown). For all vaccine strains, the ratios of HAI GMT for each lot-to-lot comparison of lots 1, 2, and 3 were between 0.94 and 1.04; thus, acceptable manufacturing consistency was demonstrated in accordance with the predefined criteria, and all subsequent analyses were performed on the pooled responses of HD vaccine recipients.
Prevaccination HAI GMTs were similar in the HD and SD vaccine groups (table 2) . In contrast, HAI GMTs at 28 days after vaccination were higher in the HD vaccine group than in the SD vaccine group for all 3 strains. The HAI GMT ratios were 1.7 (95% CI, 1.6-1.8) for A/H1N1, 1.8 (95% CI, 1.7-2.0) for A/H3N2, and 1.3 (95% CI, 1.2-1.4) for strain B. The absolute difference between the HD group and the SD group with respect to the percentage of subjects who experienced seroconversion was 25.4% for A/H1N1, 18.4% for A/H3N2, and 11.8% for B. Thus, in terms of GMT ratios and rates of seroconversion, HD vaccine met superiority criteria for the 2 A strains and showed noninferiority for the B strain; it demon- NOTE. Superiority was demonstrated if the lower limit of the 95% confidence interval for the difference in seroconversion rates (i.e., HD vaccine minus SD vaccine) was 110%, and noninferiority was shown if the lower limit was 1Ϫ10 %. The ratios of the hemagglutination inhibition (HAI) geometric mean titers (GMT) for HD vaccine and SD vaccine were assessed for all vaccine strains. Superiority was demonstrated if the lower limit of the 95% confidence interval for the ratio was 11.5, and noninferiority was defined as an HAI GMT ratio value 10.67. For HD vaccine to be considered superior to SD vaccine overall, for each measure it was required to demonstrate superiority for at least 2 of the 3 vaccine strains without demonstrating inferiority for any strain. CI, confidence interval. a n values are the number of subjects used for the immunogenicity analysis (i.e., the counts of subjects as randomized rather than as actually vaccinated; see figure 1A ). b Paired samples with prevaccination (day 0) HAI titer !1:10 and postvaccination (day 28) titer у1:40 or a у4-fold increase from day 0 to day 28. c Postvaccination samples with HAI GMT у1:40 strated overall superiority in accordance with predefined criteria. Seroprotective titers for all 3 virus strains were also achieved in a significantly greater proportion of subjects who received HD vaccine than subjects who received SD vaccine ( Post hoc analyses were conducted to determine whether sex, age, or the presence of cardiopulmonary disease influenced the immune response. Female subjects experienced a greater response to both vaccines than did males, but both males and females experienced a greater response to HD vaccine than to SD vaccine (table 3) . There were no statistically significant differences in postvaccination HAI GMTs in subsets of subjects у75 years of age and those with history of cardiopulmonary disease, compared with younger subjects and those without cardiopulmonary disease. However, the improved immunogenicity of HD vaccine, relative to SD vaccine, was maintained in the subsets of subjects у75 years of age and subjects with a history of cardiopulmonary disease. The HD vaccine also elicited greater responses in subjects with prevaccination titers Vaccine safety. Recipients of HD vaccine reported higher rates of local reactions than did SD vaccine recipients during the first 7 days after vaccination (figure 2). For both groups, the most commonly reported reaction was pain; pain of any intensity was reported by 915 (36%) of 2572 HD vaccine recipients and 306 (24%) of 1260 SD vaccine recipients. For the majority of subjects, the pain was of mild intensity and resolved within 3 days; by day 4, only 65 (3%) of 2569 subjects in the a N values are the number of subjects used for the immunogenicity analysis (i.e., the counts of subjects as randomized rather than as actually vaccinated; see figure 1A ). maximal zone size of erythema or swelling was р5 mm, and the difference in mean maximum pain scores was very modest (1.12 vs. 1.08). The rate for any solicited systemic reaction (i.e., fever, headache, malaise, or myalgia) during the first 7 days after vaccination was not significantly different when HD and SD vaccine recipients were compared (34% vs. 29%) (table 4). Most systemic reactions were mild and resolved within 3 days. The predefined criteria indicated that HD vaccine was noninferior to SD vaccine with respect to headache, malaise, myalgia (any or moderate to severe), and any fever, but inferior to SD vaccine with respect to moderate to severe fever, with a relative risk of 3.6 (95% CI, 1.25-10.08) (table 4) . However, the number of subjects with moderate or severe fever was relatively low-29 (1.1%) of 2569 subjects in the HD vaccine group and 4 (0.3%) of 1258 in the SD vaccine group-and most fever reactions were moderate, with only 1 report of severe fever in each vaccine group. Also, the mean and median temperatures in the 2 groups during days 0-7 were the same (36.2ЊC and 36.3ЊC, respectively).
The rate of unsolicited adverse events within 28 days after vaccination was comparable for the 2 vaccine groups; such events were reported by 559 (22%) of 2563 subjects in the HD group and 276 (22%) of 1252 subjects in the SD group. Of these, 129 (23%) of the events in the HD group and 58 (21%) of the events in the SD group were considered to be related to vaccination. During the 6-month follow-up period, SAEs were reported less commonly by HD vaccine recipients (159 [6%] of 2541) than by SD vaccine recipients (93 [7%] of 1240). Two SAEs were deemed related to vaccination; a 72-year-old woman with a history of Crohn disease experienced an exacerbation requiring hospitalization 2 days after receiving HD vaccine, and an 83-year-old man was diagnosed with myasthenia gravis ∼1 month after receiving SD vaccine. A total of 23 deaths occurred, all of which were considered unrelated to vaccination; the deaths were distributed equally among the 2 vaccine groups (16 [0.6%] of 2573 who received HD vaccine and 7 [0.6%] of 1260 who received SD vaccine died). There was no statistically significant difference between the HD group and the SD group with respect to healthcare use during the 6-month period after vaccination.
DISCUSSION
Despite increasing rates of vaccination among older and highrisk adults, the rates of influenza-associated morbidity and mortality continue to increase, sparking debate regarding the efficacy of currently licensed vaccines [1, 17] . Although the precise efficacy of influenza vaccine remains controversial, it appears that efficacy is diminished in older age groups [18] . The presence of chronic diseases, medication use, poor nutrition, and immunosenescence likely all play a role in decreased vaccine responsiveness. A recent review of antibody response in 31 influenza vaccine studies conducted from 1986 to 2002 concluded that elderly adults were 2-4 times less likely to seroconvert or achieve protective HAI titers after vaccination, compared with young adults [6] . Approaches to improving immune response, including live, cold-adapted influenza vaccines, new adjuvants, and virosomal vaccines, have met with mixed success [19] [20] [21] [22] . In the present study of older adults, HD vaccine induced significantly higher levels of serum antibody response than did SD influenza vaccine, confirming and extending the results of preliminary studies [11, 14] . Superior immune responses to HD vaccine were demonstrated by both the higher rates of seroconversion and the GMT ratios for the 2 influenza A virus strains included in the HD vaccine. Improved immunogenicity was demonstrated for subjects у75 years old and those with cardiopulmonary disease; these groups are considered to be at the highest risk of influenza-related complications, Melanie Saville for analysis and interpretation of results. Lastly, we are grateful to the many study volunteers who participated in this trial.
